Clinical Trial Update: Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE) [Phase 2]

View source ↗

Summary

A Phase II trial evaluating upfront chemotherapy followed by neoadjuvant short-course radiotherapy for resectable rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Rectal Carcinoma | Phase 2 | Status: COMPLETED